WCLC 2025 - Posters & ePosters-EP.06.34 Retrospective Analysis of Genomic Testing and Survival Outcomes in Lung Cancer Patients From Western India

EP.06.34 Retrospective Analysis of Genomic Testing and Survival Outcomes in Lung Cancer Patients From Western India

Pdf Summary

This retrospective study analyzed genomic testing and survival outcomes among 2,281 lung cancer patients from community oncology centers in Western India between March 2018 and September 2024. The primary focus was to compare comprehensive genomic profiling (CGP) with cost-effective short molecular panel testing in identifying actionable mutations and influencing patient survival, highlighting precision medicine's role in a developing country context.<br /><br />The cohort had a mean age of 65 years, with 94.9% diagnosed with non-small cell lung cancer (NSCLC), predominantly adenocarcinoma (85.2%). Patients were mostly diagnosed at stage IV (77.6%). Molecular testing was performed in 1,461 patients: 52.5% underwent CGP, while 47.5% had short panel testing. Next-generation sequencing (NGS) was used in 64.05% of cases.<br /><br />Findings showed that CGP significantly outperformed short panel testing in detecting rare and actionable mutations (16.1% vs. 1.6%, p=0.001). CGP identified a broader range of genetic alterations including EGFR, ALK, ROS1, MET, KRAS, BRAF, NTRK, RET, TP53, HER2, and rare mutations like PIK3CA, STK11, RB1, and BRCA. Common mutation prevalence varied, with EGFR and TP53 mutations notable in the cohort.<br /><br />Survival analysis revealed that patients tested with CGP had improved median overall survival (mOS) of 29.2 months compared to 24.3 months for the short panel group (p=0.001). Median progression-free survival across the cohort was 16.0 months, with a median follow-up of 29 months.<br /><br />In conclusion, this study from a resource-limited setting demonstrates that CGP offers superior mutation detection and is associated with better survival outcomes in lung cancer patients. These findings underscore the importance of expanding access to comprehensive genomic testing to enhance personalized precision oncology in developing countries.

Asset Subtitle

Udip Maheshwari

Meta Tag

Speaker Udip Maheshwari

Topic Pathology and Biomarkers

Keywords

lung cancer

genomic testing

comprehensive genomic profiling

short molecular panel

non-small cell lung cancer

actionable mutations

next-generation sequencing

survival outcomes

precision medicine

developing countries